Table 1. Baseline participant characteristics, stratified by presence or absence of a PCSK9 loss-of-function variant.
Includes 10,924 Black REGARDS participants.
| Characteristic | PCSK9 Variant Status | ||
|---|---|---|---|
| Present (n = 244) |
Absent (n = 10,680) |
P value | |
| Age (yrs)–mean (SD) | 64 (9.1) | 64 (9.2) | .52 |
| Gender (%) | .93 | ||
| Male | 38.1 | 38.4 | |
| Female | 61.9 | 61.6 | |
| Education (%) | .10 | ||
| Less than High School | 6.5 | 8.7 | |
| High School | 28.3 | 22.8 | |
| Some College | 32.6 | 29.6 | |
| College or more | 32.6 | 38.9 | |
| Income (%) | .31 | ||
| <$20k | 30.3 | 26.4 | |
| $20k-$34k | 28.3 | 26.4 | |
| $35-$74k | 22.1 | 25.8 | |
| ≥$75k | 6.6 | 9.2 | |
| Not Available | 12.7 | 12.3 | |
| Geographic Region (%) | .92 | ||
| Non-Stroke Belt or Buckle | 48.8 | 48.9 | |
| Stroke Belt | 34.4 | 33.5 | |
| Stroke Buckle | 16.8 | 17.7 | |
| Alcohol Use (%) | .36 | ||
| None | 76.1 | 72.0 | |
| Moderate | 21.4 | 25.5 | |
| Heavy | 2.6 | 2.5 | |
| Smoking (%) | .18 | ||
| Never | 47.7 | 45.3 | |
| Past | 32.1 | 37.5 | |
| Current | 20.2 | 17.2 | |
| Comorbidities (%) | |||
| Atrial Fibrillation | 5.9 | 7.8 | .27 |
| Chronic Lung Disease | 9.8 | 7.8 | .23 |
| Coronary Artery Disease | 11.2 | 15.6 | .07 |
| Deep Vein Thrombosis | 5.8 | 4.9 | .55 |
| Diabetes Mellitus | 34.0 | 30.5 | .23 |
| Chronic Kidney Disease | 13.5 | 12.1 | .49 |
| Dyslipidemia | 26.2 | 54.3 | < .001 |
| Hypertension | 70.1 | 71.4 | .66 |
| Obesity | 62.1 | 62.8 | .85 |
| Stroke | 7.8 | 4.9 | .09 |
| Peripheral Artery Disease | 2.5 | 2.4 | .93 |
| Biomarkers | |||
| LDL Cholesterol mg/dL (mean, SD) | 84.8 (32.0) | 117 (36.2) | < .001 |
| HDL Cholesterol mg/dL (mean, SD) | 53.8 (16.0) | 53.4 (16.0) | .73 |
| Total Cholesterol mg/dL (mean, SD) | 161 (35.1) | 194 (41.0) | < .001 |
| Triglycerides mg/dL (mean, SD) | 111 (58.3) | 113 (73.5) | .59 |
| Estimated Glomerular Filtration Rate mL/min/1.73 m2 (mean, SD) | 87.8 (24.5) | 88.4 (23.6) | .73 |
| Cystatin C >1.12 mg/dL (%) | 23.7 | 27.8 | .16 |
| hsC-reactive protein >3.0 mg/dL (%) | 45.5 | 48.3 | .38 |
| Lipid Lowering Medication Use | |||
| Cholestyramine | 0.0 | 0.1 | .69 |
| Ezetimibe | 0.8 | 2.6 | .08 |
| Fibrates | 0.0 | 1.0 | .12 |
| Statins | 13.1 | 29.5 | <0.001 |